News for Annovis Bio, Inc. (07X.F)

BERWYN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), ...

Toward the end of trading Thursday, the Dow traded up 0.87% to 30,990.49 while the NASDAQ rose 0.96% to 13,740.78. The S&P also rose, gaining 0.85% to ...

Today's Daily Dose brings you news about encouraging results of Cassava's Alzheimer's trial; FDA approval of DURECT's post-operative pain relief depot product, Posimir, Immunovant pausing IMVT-1401 trials and Travere's pivotal study of Sparsentan in focal segmental glomerulosclerosis yielding positive results.